Actively Recruiting
Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis
Led by Nanfang Hospital, Southern Medical University · Updated on 2026-06-03
500
Participants Needed
1
Research Sites
21 weeks
Total Duration
On this page
Sponsors
N
Nanfang Hospital, Southern Medical University
Lead Sponsor
C
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are investigating the key molecular factors that affect the prognosis of malignant tumors by combining detailed clinical information with advanced molecular data. This observational study aims to build precise models to predict outcomes, find potential treatment targets, and improve clinical care for adult patients who have received antitumor therapy at a single hospital between January 2017 and December 2025. The study collects clinical data such as patient demographics, tumor pathology, treatment history, and survival follow-up from electronic medical records. It also gathers tumor tissue or blood samples for various laboratory tests including sequencing, staining, ELISA, drug sensitivity testing, and flow cytometry. These tests help characterize the genetic makeup, immune environment, and cell diversity of the tumors. Participants have received different treatments such as immunotherapy, radiotherapy, or surgery, sometimes combined with chemotherapy or targeted therapy. Participants will be involved through data collection from medical records and biological samples. Researchers will monitor overall survival for up to five years from treatment start, along with progression-free survival and responses after surgery following neoadjuvant therapy. This study includes follow-up assessments to understand clinical outcomes and tumor characteristics in detail, contributing to more personalized cancer care strategies.
CONDITIONS
Brief Title
Correlation Analysis of Gene Characteristics of Malignant Tumors With Prognosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Voluntarily sign the informed consent form.
- Received treatment at Nanfang Hospital, Southern Medical University between January 2017 and December 2025.
- Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2.
- Have leftover routine tumor tissue samples or blood samples available for analysis.
You will not qualify if you...
- Patients considered unsuitable for participation by the investigator.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Varies by treatment modality and patient condition
Participants receive immunotherapy, radiotherapy, or undergo surgery as part of their treatment for malignant tumors.
Visit schedule depends on treatment type and clinical care
Duration - Typically 4 to 6 weeks after completion of neoadjuvant therapy
Participants who undergo surgery are followed up to assess pathological response and recovery.
1 to 2 visits depending on surgical and treatment course
Duration - Up to 5 years
Participants are monitored for overall and progression-free survival for up to 5 years following treatment initiation.
Periodic visits for follow-up assessments
Trial Site Locations
Total: 1 location
1
Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Actively Recruiting
Research Team
W
Wei Wang Wang
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here